Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.64 |
| ▸ | FAAH | O00519 | 6/20 | 0.50 |
| ▸ | MGLL | Q99685 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | XBP1 | P17861 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21450341 | 1.00 | PTGS1 (0.64) | PTGS1PTGS2FAAHMGLLALDH1A1 | |
| SCHEMBL14957180 | 0.97 | PTGS1 (0.68) | PTGS1PTGS2FAAHMGLLALDH1A1 | |
| SCHEMBL27175515 | 0.90 | PTGS1 (0.50) | PTGS1PTGS2FAAHMGLLALDH1A1 | |
| SCHEMBL25873335 | 0.90 | PTGS1 (0.57) | PTGS1PTGS2FAAHMGLLALDH1A1 | |
| SCHEMBL24581267 | 0.88 | PTGS1 (0.49) | PTGS1PTGS2FAAHMGLLALDH1A1 | |
| SCHEMBL30963644 | 0.88 | PTGS1 (0.49) | PTGS1PTGS2FAAHMGLLALDH1A1 | |
| SCHEMBL31309882 | 0.88 | PTGS1 (0.49) | PTGS1PTGS2FAAHMGLLALDH1A1 | |
| SCHEMBL16485229 | 0.87 | PTGS1 (0.54) | PTGS1PTGS2FAAHMGLLALDH1A1 | |
| SCHEMBL21882943 | 0.87 | PTGS1 (0.54) | PTGS1PTGS2FAAHMGLLALDH1A1 | |
| SCHEMBL23106271 | 0.87 | PTGS1 (0.54) | PTGS1PTGS2FAAHMGLLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606634-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate which binds caludin-6 and claudin-9 | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-21 | — | — | US | disclosed |
| US-12350344-B2 | Methods of treating a tumor by administering a claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-08 | — | — | US | disclosed |
| US-20250114647-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING SUBSTITUTED BENZO[e]PYRROLO[1,2-a][1,4]DIAZEPINES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-04-10 | — | — | US | disclosed |
| US-12246196-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-03-11 | — | — | US | disclosed |
| US-20240299573-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-12 | — | — | US | disclosed |
| CN-116999573-A | Antibody-drug conjugate, preparation method thereof, pharmaceutical composition and application thereof in preparation of drugs for treating tumors | 第一三共株式会社 | 2023-11-07 | — | — | CN | disclosed |
| CN-116999572-A | Antibody-drug conjugate, pharmaceutical composition and application thereof in preparation of drugs for treating tumors | 第一三共株式会社 | 2023-11-07 | — | — | CN | disclosed |
| CN-117003875-A | Antibody or functional fragment thereof, polynucleotide, expression vector, host cell, sugar chain reconstruction antibody, pharmaceutical composition and application | 第一三共株式会社 | 2023-11-07 | — | — | CN | disclosed |
| CN-111164208-B | Antibody-pyrrolobenzodiazepine derivative conjugates | 第一三共株式会社 | 2023-08-04 | — | — | CN | disclosed |
| US-11628223-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-04-18 | — | — | US | disclosed |
| US-9592240-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160129013-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEAGEN INC. | 2016-05-12 | — | — | US | disclosed |
| US-20160129013-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEAGEN INC. | 2016-05-12 | — | — | US | disclosed |
| US-9242013-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242013-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2016-01-26 | — | — | US | disclosed |
| EP-2558127-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | Seattle Genetics, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20130028919-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SPIROGEN DEVELOPMENTS SÀRL (CH) | 2013-01-31 | — | — | US | disclosed |
| US-20130028919-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SPIROGEN DEVELOPMENTS SÀRL (CH) | 2013-01-31 | — | — | US | disclosed |
| WO-2011130613-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEATTLE GENETICS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130613-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEATTLE GENETICS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160129013-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | QDPR, SBDS, DNPEP | PTGS1 4460/4885PTGS2 4243/4885FAAH 461/4885 |
| US-12606634-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate which binds caludin-6 and claudin-9 | SIGLEC9, DSG1, VSIG8 | PTGS1 4035/4885PTGS2 4258/4885FAAH 1147/4885 |
| US-20240299573-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | PTGS1 4202/4885PTGS2 3863/4885FAAH 1914/4885 |
| US-11628223-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines | GABRA1, GABRA4, GABRA2 | PTGS1 2896/4885PTGS2 3498/4885FAAH 366/4885 |
| US-12350344-B2 | Methods of treating a tumor by administering a claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugate | EPCAM, PDCD6, JUP | PTGS1 2410/4885PTGS2 2064/4885FAAH 1969/4885 |
| US-12246196-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines | CNTN1, BTN3A1, FABP6 | PTGS1 3125/4885PTGS2 3653/4885FAAH 2089/4885 |
| US-20250114647-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING SUBSTITUTED BENZO[e]PYRROLO[1,2-a][1,4]DIAZEPINES | CNTN1, BTN3A1, FABP6 | PTGS1 3123/4885PTGS2 3654/4885FAAH 2078/4885 |
| US-20130028919-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | QDPR, SBDS, DNPEP | PTGS1 4460/4885PTGS2 4243/4885FAAH 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.